Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Cisplatin
Drug ID BADD_D00474
Description Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.
Indications and Usage For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.
Marketing Status approved
ATC Code L01XA01
DrugBank ID DB00515
KEGG ID D00275
MeSH ID D002945
PubChem ID 5702198
TTD Drug ID D0U5HU
NDC Product Code 16729-288; 25021-253; 0143-9505; 68554-0077; 0143-9504; 68001-283; 44567-509; 50711-0001; 44567-510; 63323-103; 0703-5747; 0703-5748; 44567-530; 60505-6277; 68083-163; 44567-511; 49452-2078; 54875-0001; 67184-0010; 68083-162; 70860-206; 49812-0009; 72659-864
UNII Q20Q21Q62J
Synonyms Cisplatin | cis-Diamminedichloroplatinum(II) | Platinum Diamminodichloride | Diamminodichloride, Platinum | cis-Platinum | cis Platinum | Dichlorodiammineplatinum | cis-Diamminedichloroplatinum | cis Diamminedichloroplatinum | cis-Dichlorodiammineplatinum(II) | NSC-119875 | Platino | Platinol | Biocisplatinum | Platidiam
Chemical Information
Molecular Formula PtCl2(NH3)2
CAS Registry Number 15663-27-1
SMILES N.N.Cl[Pt]Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Tumour lysis syndrome16.32.03.002; 14.05.01.0040.001007%
Tympanic membrane perforation12.01.14.001; 04.05.04.0010.000246%Not Available
Type I hypersensitivity10.01.03.0060.000224%Not Available
Ulcer08.03.06.0010.000280%Not Available
Unresponsive to stimuli17.02.05.0310.000392%Not Available
Ureteric cancer20.06.01.008; 16.08.05.0020.000112%Not Available
Ureteric obstruction20.06.01.0050.000224%Not Available
Urinary incontinence17.05.01.008; 20.02.02.0100.000224%
Urine abnormality20.02.01.0130.000302%Not Available
Urogenital disorder21.10.05.010; 20.08.01.0020.000224%Not Available
Uterine cancer21.07.02.003; 16.12.05.0010.000168%Not Available
Vaginal haemorrhage24.07.03.005; 21.08.01.0010.000895%
Vasculitis24.12.04.027; 10.02.02.0060.000112%
Vasodilatation24.03.02.003; 23.06.05.0060.000112%Not Available
Vein disorder24.03.02.0150.000381%Not Available
Vena cava thrombosis24.01.10.0010.000168%Not Available
Venoocclusive liver disease12.02.09.039; 24.04.07.002; 09.01.06.0020.000224%
Venous thrombosis24.01.01.0080.000168%Not Available
Vision blurred17.17.01.010; 06.02.06.007--
Visual impairment06.02.10.013--Not Available
Vomiting07.01.07.0030.017618%
Weight gain poor14.03.02.0180.000168%Not Available
Wheezing22.03.01.009--
Mental status changes19.07.01.0010.000504%Not Available
Cardiotoxicity02.11.01.009; 12.03.01.0070.000560%Not Available
Lymphocele24.09.02.002; 01.09.01.0080.000168%
Deafness unilateral04.02.01.0110.000358%Not Available
Hypoacusis04.02.01.0060.001019%
Performance status decreased08.01.03.0420.000392%Not Available
Retinal toxicity12.03.01.036; 06.09.03.0130.001567%Not Available
The 13th Page    First    Pre   13 14 15 16 17    Next   Last    Total 20 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene